Pashkov Vitalii, Kotvitska Alla, Harkusha Andrii
Poltava Law Institute Of Yaroslav Mudryi National Law University, Poltava, Ukraine.
National University Of Pharmacy, Kharkiv, Ukraine.
Wiad Lek. 2017;70(3 pt 2):614-618.
The need for effective legal regulation of production and sale of medical products in Ukraine due to its social effect is obvious and requires a high level of clarity. The experience of more advanced countries in this area, given the way chosen by Ukraine to harmonize our laws with EU legislation, is certainly could be a useful source of information. The urgency of issues need further intensification of national legal reforms. Some key points on concept of legal regulation of abovementioned sphere is a base of this study.
Legislation of Ukraine, European Union, United States of America, Guidelines, developed by European Commission & Food and Drug Administration's (FDA), recommendations represented by international voluntary group and scientific works. This article is based on dialectical, comparative, analytic, synthetic and comprehensive research methods.
This study provide a possibility to state that main difference of regulatory systems in EU and US is that the legal framework of the EU is more flexible. This flexibility is grounded on main principle that only basic quality requirements for medical devices is defined by legislative acts however more detailed requirements are defined in standards, technical regulations, specifications, which are discretionary in nature. Contractors are free to choose any technical solution that provides compliance with the essential requirements, they can choose among different conformity assessment procedures and between accredited conformity assessment bodies to which they want to apply. The contractors themselves is interested to pass the conformity assessment procedure and have the right to put a conformity mark on their medical device because it will give them a real competitive advantage. In contrast, US State regulatory system provides strict control over business entities and law act establishes the quality requirements of medical products. The only body that can authorize the introduction of medical products and perform post-market monitoring is Food and Drug Administration (FDA), which has almost unlimited competence in this sphere.
Taking into account further deepening of the European integration process of Ukraine, establishing of the regulatory system as much similar to that of the EU as possible is a main goal of legal reforms in abovementioned sphere. On the one hand, such system allows to implement effective control of contractors in the sphere of production and sale of medical products and provide safety of medical devices that are introduced, on the other hand, it does not afflict contractors with excessive and total control, allowing them to choose behavior that is most acceptable, understandable and user-specific. However, US's experience also has some positive characteristics, which could be taken into account. Therefore, such complex symbiosis of approaches from our point of view will balance controversial interest of manufacturers, sellers and consumers of medical devices.
鉴于其社会影响,乌克兰对医疗产品生产和销售进行有效法律监管的必要性显而易见,且需要高度的明确性。鉴于乌克兰选择的使本国法律与欧盟立法协调一致的方式,该领域更先进国家的经验无疑是有用的信息来源。这些问题的紧迫性需要进一步加强国家法律改革。上述领域法律监管概念的一些关键点是本研究的基础。
乌克兰、欧盟、美利坚合众国的立法、欧盟委员会和美国食品药品监督管理局(FDA)制定的指南、国际自愿组织提出的建议以及科学著作。本文基于辩证、比较、分析、综合和全面的研究方法。
本研究表明,欧盟和美国监管体系的主要差异在于欧盟的法律框架更为灵活。这种灵活性基于一项主要原则,即立法行为仅定义医疗器械的基本质量要求,而更详细的要求则在标准、技术法规、规范中定义,这些本质上是可自由裁量的。承包商可自由选择任何能满足基本要求的技术解决方案,他们可以在不同的合格评定程序之间进行选择,也可以在他们希望申请的认可合格评定机构之间进行选择。承包商自身有兴趣通过合格评定程序,并有权在其医疗器械上贴上合格标志,因为这将给他们带来真正的竞争优势。相比之下,美国的国家监管体系对商业实体进行严格控制,法律行为规定了医疗产品的质量要求。唯一能够批准医疗产品上市并进行上市后监测的机构是食品药品监督管理局(FDA),其在该领域几乎拥有无限的权限。
考虑到乌克兰欧洲一体化进程的进一步深化,建立尽可能与欧盟相似的监管体系是上述领域法律改革的主要目标。一方面,这样的体系能够在医疗产品生产和销售领域对承包商实施有效控制,并确保所引入医疗器械的安全;另一方面,它不会给承包商带来过度和全面的控制,允许他们选择最可接受、最易懂且最符合用户需求的行为方式。然而,美国的经验也有一些积极特点,值得考虑。因此,从我们的角度来看,这种方法的复杂共生将平衡医疗器械制造商、销售商和消费者相互冲突的利益。